Peptide-drug conjugates offer targeted cancer treatment with better tumor penetration and simpler manufacturing than antibody-drug conjugates.
Better tumor penetrationPDCs' smaller size compared to antibody-drug conjugates allows deeper penetration into solid tumors
What the researchers found
Peptide-drug conjugates represent a promising targeted cancer therapy approach, offering specificity, deeper tumor penetration, and simpler manufacturing compared to antibody-based delivery systems.
Why it matters
Traditional chemotherapy damages healthy cells along with cancer cells. PDCs aim to deliver drugs only to tumors, which could mean better treatment with fewer side effects.
The numbers in context
Not applicable — comprehensive review of the PDC field and design principles.
How the study worked
Comprehensive review of PDC design, chemistry, and drug delivery system applications in cancer theranostics.
Who was studied
Review of preclinical and clinical PDC research in cancer
What this study cannot tell us
Most PDC data comes from preclinical studies. Clinical translation faces challenges including stability in the bloodstream and manufacturing scale-up.
How to read the evidence
Rated preliminary: comprehensive review of an emerging field with most data from preclinical studies. Few PDCs have reached clinical trials.
When this study was published
Published in 2024. Reviews the state of a rapidly developing field in targeted cancer therapy.
The bigger picture
Targeted drug delivery is the future of cancer treatment. PDCs fill a niche between small molecule drugs and large antibody conjugates, offering a middle ground that combines targeting with practical advantages.
Questions still open
- Can PDCs achieve the same tumor specificity as antibody-based approaches?
- Which tumor types are best suited for PDC therapy?
Common questions
What is a peptide-drug conjugate?
How do PDCs compare to antibody-drug conjugates?
Read the original research
Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic.
ACS pharmacology & translational science, 7(2), 309-334
Citation
Rizvi, Syed Faheem Askari; Zhang, Linjie; Zhang, Haixia; Fang, Quan. (2024). Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic.. ACS pharmacology & translational science, 7(2), 309-334. https://doi.org/10.1021/acsptsci.3c00269